Diabetes Dance Dare
Dancing is way better than dumping ice on your head...
This is Arden and her friend Nadia doing the Diabetes Dance Dare for the American Diabetes Association. The ADA does so many great things fort he diabetes community including providing legal counsel for children who are being treated poorly at school. #DiabetesDanceDare
I can't dance so I enlisted Arden...
Make your own video today, share on social media and tag #DiabetesDanceDare, @amdiabetesassn and dare three people to make a video of their own.
I'm daring you!
100,000 downloads and counting!
Thank you for listening!
Available everywhere that podcasts are heard...
News: U.K. Airline Pilots Fit to Fly With Type 1 Diabetes
from MedPage - Ed Susman, Contributing Writer, MedPage Today
MUNICH – Commercial airline pilots flying withinsulin-controlled diabetes had no incidents of medical incapacitation in more than 18 months of study, researchers reported here.
Of the 26 insulin-treated pilots flying planes under the U.K. flag, a total of 8,897 blood glucose monitoring values had been recorded during 4,900 flight hours with more than 96% of the cockpit glucose monitoring readings indicating pilots with diabetes were in the "Green Zone" for safety, reported Julia Hine, MD, of the Royal Surrey County Hospital in Guildford, England.
In a presentation at the European Association for the Study of Diabetes, Hine said that for short and medium haul flights -- those of less than 6 hours duration -- 96% of 7,829 blood glucose monitoring readings were within the safe range. For long haul flights, 97% of 1,068 readings were within that "green" range.
The entire article is avail able here.
First Patients Enrolled in Clinical Trial for Omnipod Artificial Pancreas System
Look out future... Here come the Podders!
BILLERICA, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ:PODD) (Insulet or the Company), the leader in tubeless insulin pump technology with its Omnipod® Insulin Management System (Omnipod System), today announced the first patient has completed the feasibility study of the Omnipod Horizon™ Automated Glucose Control System (Omnipod Horizon System). The full study will evaluate the use of a personal Model Predictive Control algorithm with the Omnipod platform in 20 adults with type 1 diabetes and is taking place in a clinical research center setting to gather data to be used to evolve the algorithm in subsequent studies leading to FDA submission.
“We are very excited to be participating in Insulet’s artificial pancreas clinical trials,” said Jordan Pinsker, M.D., senior research physician at William Sansum Diabetes Center. “Working with Professor Francis J. Doyle III and Dr. Eyal Dassau, Sansum played a major role in the development of the original UC Santa Barbara Artificial Pancreas algorithm that Insulet acquired. We look forward to contributing to the clinical and development pathway as Insulet takes this promising technology to a commercial product.”
The Omnipod Horizon System will combine best-in-class technologies into one integrated system consisting of an on-body Omnipod tubeless pump, the latest Dexcom continuous glucose monitoring (CGM) technology, a modified version of Insulet’s handheld controller and state-of-the-art security system architecture. Insulet’s Omnipod Horizon System is unique in that the algorithm looks toward the future horizon of blood glucose levels, reacting quickly and efficiently to adjust insulin delivery to optimize outcomes for each user. The system will provide the same proven lifestyle benefits as the current Omnipod System, such as the discreet, reliable, tubeless form factor and up to three days of non-stop insulin delivery to make it easy to stay connected and avoid disruption of insulin delivery during routine activities like exercising and bathing.
“Our new Omnipod Horizon System is designed to deliver not only improved clinical outcomes, but the greatly desired improvement in quality of life for those living with insulin-dependent diabetes,” said Patrick Sullivan, President and Chief Executive Officer. “With the first clinical study of our innovative artificial pancreas underway, we have taken another important step in fulfilling our mission to improve the lives of people with diabetes.”
Voluntary Glucagon Recall: GlucaGen
Hey everyone,
I'm passing on some voluntary recall news from Novo Nordisk. If you have their GlucaGen glucagon kit you may want to read on. The text below is the info that I thought to be pertinent from the press release - the entire release can be found here.
Take note of the company's estimation that, "of the 71,215 pens being recalled, four pens could be defective".
Novo Nordisk Inc. issues voluntary nationwide recall of six batches of GlucaGen® HypoKit® (glucagon [rDNA origin] for injection) due to detached needles on the syringe in the kit.
PLAINSBORO, N.J., Sept. 8, 2016 /PRNewswire/ -- Novo Nordisk Inc. is recalling six batches of the GlucaGen®HypoKit® in the U.S. due to two customer complaints from the UK and Portugal involving detached needles on the syringe with Sterile Water for Injection (SWFI). GlucaGen® HypoKit® is indicated for the treatment of severe hypoglycemia (low blood sugar) in patients with diabetes who are treated with insulin. A syringe with a detached needle cannot be used as prescribed.
Untreated hypoglycemia can eventually lead to unconsciousness and seizures, which can prove fatal. If the blood glucose levels are not quickly restored, continuing hypoglycemia can lead to a decline in brain glucose levels which manifests through a variety of symptoms including cognitive dysfunction, sweating, tremors, convulsion and eventually coma or death.
Novo Nordisk conducted an investigation which showed that a small number (0.006%) of needles could be detached from the syringe in certain batches of GlucaGen® HypoKit®. To protect patient safety, Novo Nordisk is recalling affected batches from wholesalers, pharmacies and patients in the U.S.
It is estimated that out of the 71,215 pens being recalled, four pens could be defective.
This recall includes GlucaGen® HypoKit® batch numbers:
Batch: FS6X270, Expiry: 09/30/2017
Batch: FS6X296, Expiry: 09/30/2017
Batch: FS6X538, Expiry: 09/30/2017
Batch: FS6X597, Expiry: 09/30/2017
Batch: FS6X797, Expiry: 09/30/2017
Batch: FS6X875, Expiry: 09/30/2017
The affected products were distributed starting February 15, 2016.
Novo Nordisk is working as quickly as possible and in collaboration with the U.S. Food and Drug Administration (FDA) to recall affected products from the marketplace, including those in the possession of patients. To date, Novo Nordisk is not aware of any known adverse events resulting from the use of the recalled batches.
Patients or caregivers should check the batch number to see if their GlucaGen® HypoKit® is affected. The batch number is printed on the GlucaGen® HypoKit® as indicated below in the red box (Figure 1).
Figure 1. A) GlucaGen® HypoKit® where the batch number is found in the red box, B) close up of the batch number.
If you have a GlucaGen® HypoKit® with one of the above-mentioned batch numbers, call 1-888-840-1137 from Monday to Friday, between 8:30am – 6:00pm Eastern Time, to find out how to return the product. Novo Nordisk will provide reimbursement for out-of-pocket costs incurred for the purchase for your affected GlucaGen® HypoKit® with proof of purchase. If you received a GlucaGen® HypoKit® through the Novo Nordisk Patient Assistance Program, you will receive a replacement device.
If you are in possession of a GlucaGen® HypoKit® with a batch number NOT mentioned above, the product is not subject to the recall and may be used as prescribed.
Novo Nordisk Inc. is notifying its distributors and customers by letter and phone and is arranging for return of all recalled products.
Adverse reactions or quality problems experienced with the use of this product may be reported to Novo Nordisk by calling 1-800-727-6500. Patients can also call the FDA's MedWatch Adverse Event Reporting program either online, by regular mail or by fax.
Complete and submit the report Online: www.fda.gov/medwatch/report.htm
Regular Mail or Fax: Download form www.fda.gov/MedWatch/getforms.htm or call 1-800-332-1088 to request a reporting form, then complete and return to the address on the pre-addressed form, or submit by fax to 1-800-FDA-0178.
This recall is being conducted with the knowledge of the U.S. Food and Drug Administration.
Novo Nordisk is committed to patient safety and delivering high-quality medicines, and is working to take corrective actions and avoid re-occurrence.
Click to enlarge
"Because of your podcast (Juicebox), I have significantly reduced the amount of spikes that I get."